Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03996473
Title	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Bayer
Indications	lung non-small cell carcinoma
Therapies	Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| ESP \| BEL